Your browser is no longer supported. Please, upgrade your browser.
Myriad Genetics, Inc.
Index- P/E- EPS (ttm)-2.25 Insider Own2.70% Shs Outstand76.00M Perf Week-19.70%
Market Cap1.86B Forward P/E73.17 EPS next Y0.35 Insider Trans-9.22% Shs Float73.34M Perf Month-7.54%
Income-168.70M PEG- EPS next Q-0.08 Inst Own- Short Float7.51% Perf Quarter-11.59%
Sales566.10M P/S3.28 EPS this Y63.40% Inst Trans0.16% Short Ratio8.62 Perf Half Y77.68%
Book/sh11.52 P/B2.20 EPS next Y305.90% ROA-7.70% Target Price26.00 Perf Year59.48%
Cash/sh2.41 P/C10.56 EPS next 5Y8.10% ROE-12.00% 52W Range10.54 - 33.97 Perf YTD28.39%
Dividend- P/FCF- EPS past 5Y-21.20% ROI-6.10% 52W High-24.32% Beta1.62
Dividend %- Quick Ratio2.00 Sales past 5Y-16.50% Gross Margin68.50% 52W Low143.93% ATR1.88
Employees2700 Current Ratio2.20 Sales Q/Q5.50% Oper. Margin-30.80% RSI (14)39.32 Volatility8.85% 6.42%
OptionableYes Debt/Eq0.18 EPS Q/Q66.40% Profit Margin-19.00% Rel Volume1.03 Prev Close25.39
ShortableYes LT Debt/Eq0.18 EarningsMay 03 AMC Payout- Avg Volume639.51K Price25.71
Recom3.10 SMA20-10.43% SMA50-12.00% SMA20022.92% Volume439,979 Change1.26%
Sep-26-19Downgrade BofA/Merrill Neutral → Underperform $30 → $28
Aug-14-19Downgrade Piper Jaffray Overweight → Neutral $45 → $40
Aug-02-19Upgrade BofA/Merrill Underperform → Neutral
Aug-01-19Upgrade Barclays Underweight → Equal Weight $18 → $40
Jul-29-19Downgrade Needham Strong Buy → Hold
Jul-09-19Downgrade Cowen Outperform → Market Perform
Mar-12-19Reiterated Needham Strong Buy $37 → $41
Jan-03-19Initiated Needham Strong Buy $36
Nov-30-18Upgrade Goldman Sell → Neutral
Oct-10-18Upgrade Piper Jaffray Neutral → Overweight
Jul-11-18Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-21-18Upgrade Morgan Stanley Underweight → Equal-Weight
Jan-29-18Initiated Goldman Sell $32
Jan-22-18Reiterated Barclays Equal Weight $30 → $35
Jan-05-18Initiated BTIG Research Buy $41
Oct-02-17Resumed Leerink Partners Mkt Perform $31
Aug-09-17Reiterated Barclays Equal Weight $28 → $26
Feb-08-17Upgrade Ladenburg Thalmann Sell → Neutral
Jan-18-17Initiated Deutsche Bank Sell $15
Oct-10-16Downgrade Ladenburg Thalmann Neutral → Sell
May-05-21 04:05PM  
May-04-21 08:07AM  
May-03-21 06:35PM  
Apr-28-21 07:05AM  
Apr-27-21 04:05PM  
Apr-14-21 10:38AM  
Apr-09-21 09:00AM  
Mar-31-21 08:00AM  
Mar-29-21 09:50AM  
Mar-25-21 11:30AM  
Mar-24-21 06:05PM  
Mar-23-21 09:00PM  
Mar-05-21 10:03AM  
Mar-02-21 07:05AM  
Feb-23-21 08:30PM  
Feb-22-21 10:14AM  
Feb-18-21 04:12PM  
Feb-16-21 04:05PM  
Feb-12-21 07:05AM  
Feb-11-21 04:05PM  
Feb-10-21 11:11AM  
Feb-08-21 07:05AM  
Feb-02-21 07:05AM  
Jan-28-21 12:32PM  
Jan-19-21 07:05AM  
Jan-18-21 08:45AM  
Jan-12-21 08:40AM  
Jan-11-21 02:05PM  
Jan-08-21 07:05AM  
Jan-06-21 10:20AM  
Jan-05-21 04:05PM  
Jan-04-21 07:05AM  
Dec-11-20 07:05AM  
Dec-09-20 11:30AM  
Nov-30-20 11:00AM  
Nov-17-20 07:05AM  
Nov-16-20 07:05AM  
Nov-15-20 08:00PM  
Nov-11-20 07:05AM  
Nov-10-20 08:25AM  
Nov-09-20 09:30PM  
Nov-04-20 07:05AM  
Oct-26-20 12:31PM  
Oct-16-20 09:05AM  
Oct-15-20 07:05AM  
Oct-05-20 12:11PM  
Sep-16-20 10:58AM  
Sep-12-20 11:30AM  
Sep-10-20 07:05AM  
Sep-03-20 06:21PM  
Aug-24-20 11:04AM  
Aug-21-20 07:05AM  
Aug-14-20 04:05PM  
Aug-13-20 06:15PM  
Aug-12-20 11:01AM  
Aug-10-20 07:05AM  
Aug-06-20 07:05AM  
Aug-04-20 12:30PM  
Jul-31-20 07:05AM  
Jul-29-20 07:05AM  
Jul-28-20 07:05AM  
Jul-22-20 07:05AM  
Jul-07-20 06:32PM  
Jul-06-20 10:04AM  
Jul-05-20 08:56PM  
Jul-02-20 08:46AM  
Jul-01-20 07:05AM  
Jun-29-20 11:27AM  
Jun-25-20 07:05AM  
Jun-23-20 11:19AM  
Jun-22-20 10:32AM  
Jun-17-20 11:53AM  
Jun-15-20 07:05AM  
Jun-12-20 07:48PM  
Jun-11-20 02:22PM  
Jun-09-20 10:23AM  
Jun-08-20 07:05AM  
Jun-05-20 09:00AM  
Jun-04-20 11:31AM  
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LANCHBURY JERRY SChief Scientific OfficerMay 04Option Exercise19.4719,360376,939285,282May 05 07:45 PM
LANCHBURY JERRY SChief Scientific OfficerMay 04Sale31.9719,360618,949265,922May 05 07:45 PM
LANCHBURY JERRY SChief Scientific OfficerApr 27Option Exercise19.4740,000778,800305,922Apr 28 05:10 PM
LANCHBURY JERRY SChief Scientific OfficerApr 27Sale31.4740,0001,258,800265,922Apr 28 05:10 PM
Lambert NicoleSee RemarksApr 19Sale27.016,649179,586129,119Apr 20 05:18 PM
Hart Jayne B.Chief People OfficerMar 29Option Exercise22.2758,0001,291,860108,128Mar 30 06:31 PM
Hart Jayne B.Chief People OfficerMar 29Sale30.0058,0001,740,00080,128Mar 30 06:31 PM
LANCHBURY JERRY SChief Scientific OfficerFeb 16Option Exercise18.0080,0001,440,000321,020Feb 17 06:10 PM
LANCHBURY JERRY SChief Scientific OfficerFeb 16Sale29.7180,0002,377,048246,575Feb 17 06:10 PM
Parkinson PaulEVP Strategy and InnovationJan 08Sale25.0011,824295,60076,746Jan 11 04:40 PM
Phanstiel S. LouiseDirectorNov 11Buy16.6215,000249,33666,790Nov 12 08:57 AM
Ford AlexanderChief Operating OfficerSep 15Sale13.782,80438,630151,159Sep 16 09:56 AM